Overview
- A federal securities complaint, captioned Holtzman v. Beta Bionics, seeks to represent investors who bought Beta Bionics stock from July 30, 2025 through February 24, 2026 and is pending in the U.S. District Court for the Central District of California.
- Plaintiffs link a surprise miss on new iLet patient starts that triggered a roughly 37% one‑day stock drop on January 8–9, 2026 to later regulatory disclosures that they say revealed the company had concealed material safety problems.
- The FDA’s January 28 warning letter, publicly posted on February 24, 2026, criticized Beta Bionics for failing to analyze complaint data, implement corrective actions, and timely report information that could indicate serious injury, and plaintiffs say the agency’s inspection record shows more than 18,000 user complaints including hundreds of severe hypoglycemia events.
- Beta Bionics management previously downplayed an October 2025 Form 483 as related only to complaint‑handling definitions rather than device safety, a position plaintiffs say conflicts with the FDA’s later findings and supports claims that executives misled investors.
- Multiple plaintiff firms are soliciting class members and lead‑plaintiff candidates ahead of a November 3, 2026 deadline, a fight that will determine litigation leadership, discovery priorities and whether whistleblower or SEC probes add evidence about what company insiders knew.